4 L’évaluation des marqueurs prédictifs
5 La personnalisation sur le risque de base
7 L’évaluation de l’utilité clinique par les essais de stratégie
Références
[1] Maughan T. The Promise and the Hype of 'Personalised Medicine'. New Bioeth 2017;23:13–20 10.1080/20502877.2017.1314886 [28517988]
[2] Feiler T, Gaitskell K, Maughan T, et al. Personalised Medicine: The Promise, the Hype and the Pitfalls. New Bioeth 2017;23:1–12 10.1080/20502877.2017.1314895 [28517985]
[3] Pelter MN, Druz RS. Precision medicine: Hype or hope? Trends Cardiovasc Med 2022 10.1016/j.tcm.2022.11.001 [36375778]
[4] Prasad V, Gale RP. Precision medicine in acute myeloid leukemia: Hope, hype or both? Leuk Res 2016;48:73–77 10.1016/j.leukres.2016.07.011 [27497757]
[5] Polasek TM, Shakib S, Rostami-Hodjegan A. Precision medicine technology hype or reality? The example of computer-guided dosing. F1000Res 2019;8 10.12688/f1000research.20489.1 [31754426]
[6] Joyner MJ, Paneth N. Promises, promises, and precision medicine. J Clin Invest 2019;129:946–48 10.1172/JCI126119 [30688663]
[7] Joyner MJ, Paneth N. Seven Questions for Personalized Medicine. JAMA 2015;314:999–1000 10.1001/jama.2015.7725 [26098474]
[8] Montello M. Announcement from Perspectives in Biology and Medicine. Perspect Biol Med 2018;61:465–66 10.1353/pbm.2018.0056
[9] Caulfield T. Spinning the Genome: Why Science Hype Matters. Perspect Biol Med 2018;61:560–71 10.1353/pbm.2018.0065 [30613038]
[10] Fröhlich H, Balling R, Beerenwinkel N, et al. From hype to reality: data science enabling personalized medicine. BMC Med 2018;16:150 10.1186/s12916-018-1122-7 [30145981]
[11] Brown MJ. Personalised medicine for hypertension. BMJ 2011;343:d4697 10.1136/bmj.d4697 [21798973]
[12] Hood L, Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. New Biotechnology 2012;29:613–24 10.1016/j.nbt.2012.03.004 [22450380]
[13] Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 2023:1–7 10.1038/s41586-023-06063-y [37165196]
[14] Kerr DJ, Yang L. Personalising cancer medicine with prognostic markers. eBioMedicine 2021;72:103577 10.1016/j.ebiom.2021.103577 [34563926]
[15] Oikonomou EK, Suchard MA, McGuire DK, et al. Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes. Diabetes Care 2022;45:965–74 10.2337/dc21-1765 [35120199]
[16] Superchi C, Brion Bouvier F, Gerardi C, et al. Study designs for clinical trials applied to personalised medicine: a scoping review. BMJ open 2022;12:e052926 10.1136/bmjopen-2021-052926 [35523482]
[17] Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018;379:2342–50 10.1056/NEJMoa1809697 [30280658]
[18] Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–57 10.1056/NEJMoa0810699 [19692680]
[19] Angus DC, Chang C-CH. Heterogeneity of Treatment Effect: Estimating How the Effects of Interventions Vary Across Individuals. JAMA 2021;326:2312–13 10.1001/jama.2021.20552 [34905043]
[20] Dorresteijn JAN, Visseren FLJ, Ridker PM, et al. Estimating treatment effects for individual patients based on the results of randomised clinical trials. BMJ 2011;343 10.1136/bmj.d5888 [21968126]
[21] Gewandter JS, McDermott MP, He H, et al. Demonstrating Heterogeneity of Treatment Effects Among Patients: An Overlooked but Important Step Toward Precision Medicine. Clin Pharmacol Ther 2019 10.1002/cpt.1372 [30661240]
[22] Dahly DL. Response Heterogeneity | 2019. Available at: https://darrendahly.github.io/post/2017-08-11-response-heterogeneity/ Accessed March 20, 2023.
[23] Harrell F. Statistical Thinking - Viewpoints on Heterogeneity of Treatment Effect and Precision Medicine 2023. Available at: https://www.fharrell.com/post/hteview/ Accessed March 20, 2023.
[24] Senn S. Statistical pitfalls of personalized medicine. Nature 2018;563:619–21 10.1038/d41586-018-07535-2 [30482931]
[25] Senn S. Mastering variation: variance components and personalised medicine. Stat Med 2016;35:966–77 10.1002/sim.6739 [26415869]
[26] Senn S, Rolfe K, Julious SA. Investigating variability in patient response to treatment--a case study from a replicate cross-over study. Stat Methods Med Res 2011;20:657–66 10.1177/0962280210379174 [20739334]
[27] Sundström J, Lind L, Nowrouzi S, et al. Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial. JAMA 2023;329:1160–69 10.1001/jama.2023.3322 [37039792]
[28] Mueller S, Pearl J. Personalized decision making – A conceptual introduction. Journal of Causal Inference 2023;11 10.1515/jci-2022-0050
[29] Pearl J. An introduction to causal inference. The International Journal of Biostatistics 2010;6:Article 7 10.2202/1557-4679.1203 [20305706]
[30] Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health 2005;95 Suppl 1:S144-50 10.2105/AJPH.2004.059204 [16030331]
[31] Hernán MA. A definition of causal effect for epidemiological research. J Epidemiol Community Health 2004;58:265–71 10.1136/jech.2002.006361 [15026432]
[32] Hernán M, Robins JM. Causal inference. Boca Raton: Chapman & Hall/CRC 2021 ISBN:1420076167;
[33] Ballman KV. Biomarker: Predictive or Prognostic? JCO 2015;33:3968–71 10.1200/JCO.2015.63.3651 [26392104]
[34] Janes H, Pepe MS, McShane LM, et al. The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment. JNCI Journal of the National Cancer Institute 2015;107 10.1093/jnci/djv157 [26109106]
[35] Oldenhuis CNAM, Oosting SF, Gietema JA, et al. Prognostic versus predictive value of biomarkers in oncology. European Journal of Cancer 2008;44:946–53 10.1016/j.ejca.2008.03.006 [18396036]
[36] Dobbin KK, McShane LM. Sample size methods for evaluation of predictive biomarkers. Stat Med 2022;41:3199–210 10.1002/sim.9412 [35491401]
[37] Clark GM. Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib. Mol Oncol 2008;1:406–12 10.1016/j.molonc.2007.12.001 [19383314]
[38] Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists'(FTT) Collaborative Group. The Lancet 1994;343:311–22 ; [7905143]
[39] Cross DAE, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014;4:1046–61 10.1158/2159-8290.CD-14-0337 [24893891]
[40] Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med 2020;382:41–50 10.1056/NEJMoa1913662 [31751012]
[41] Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med 2021;384:2371–81 10.1056/NEJMoa2103695 [34096690]
[42] Sachdev A, Sharpe I, Bowman M, et al. Objective response rate of placebo in randomized controlled trials of anticancer medicines. EClinicalMedicine 2023;55:101753 10.1016/j.eclinm.2022.101753
[43] Chowdary P, Shapiro S, Makris M, et al. Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B. N Engl J Med 2022;387:237–47 10.1056/NEJMoa2119913 [35857660]
[44] Gyawali B, Rome BN, Kesselheim AS. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study. BMJ 2021;374:n1959 10.1136/bmj.n1959 [34497044]
[45] Langen AJ de, Johnson ML, Mazieres J, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. The Lancet 2023;401:733–46 10.1016/S0140-6736(23)00221-0 [36764316]
[46] Joyner MJ, Paneth N (2019). Precision medicine’s rosy predictions haven’t come true. We need fewer promises and more debate. STAT, 7 February 2019. Available at: https://www.statnews.com/2019/02/07/precision-medicine-needs-open-debate/ Accessed March 19, 2023.
[47] (20180921T123000Z). Precision medicine fails for up to 93% of patients. Are its proponents selling 'false hope'? Advisory Board, 20180921T123000Z. Available at: https://www.advisory.com/daily-briefing/2018/09/21/precision-medicine Accessed March 19, 2023.
[48] Szabo L (2018). Opinion | Are We Being Misled About Precision Medicine? The New York Times, 11 September 2018. Available at: https://www.nytimes.com/2018/09/11/opinion/cancer-genetic-testing-precision-medicine.html Accessed March 19, 2023.
[49] Le Tourneau C, Delord J-P, Gonçalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. The Lancet Oncology 2015;16:1324–34 10.1016/S1470-2045(15)00188-6
[50] Chen AP, Kummar S, Moore N, et al. Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial. JCO Precision Oncology 2021;5 10.1200/PO.20.00372 [33928209]
[51] MLAK R, KRAWCZYK P, RAMLAU R, et al. Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients. Oncology Reports 2013;30:2385–98 10.3892/or.2013.2696 [23982437]
[52] Han Y, Liu J, Sun M, et al. A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis. Disease Markers 2016;2016:7643981 10.1155/2016/7643981 [27057082]
[53] Lee SM, Falzon M, Blackhall F, et al. Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET). JCO 2017;35:402–11 10.1200/JCO.2016.68.1841 [27893326]
[54] Vivot A, Boutron I, Béraud-Chaulet G, et al. Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing. Sci Rep 2017;7:6882 10.1038/s41598-017-07358-7 [28761069]
[55] Marabelle A, Fakih MG, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158. Annals of Oncology 2019;30:v477-v478 10.1093/annonc/mdz253.018
[56] Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015;372:2509–20 10.1056/NEJMoa1500596 [26028255]
[57] Nikola N, Aleksa G, Ana R, et al. Brief Report: Predictive value of PD-L1 Expression in non-Small-Cell Lung Cancer - Should we Set the Bar Higher for Monotherapy? Clinical Lung Cancer 2023;0 10.1016/j.cllc.2023.04.010 [37236852]
[58] Kim JH, Ryu M-H, Park YS, et al. Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial. BMC Cancer 2022;22 10.1186/s12885-022-09488-2 [35397540]
[59] Rothwell PM. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. The Lancet 2005;365:176–86 10.1016/S0140-6736(05)17709-5
[60] Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380–88 10.1056/NEJMoa0909530 [20573926]
[61] Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The Lancet. Oncology 2010;11:121–28 10.1016/S1470-2045(09)70364-X [20022809]
[62] Kent DM, Nelson J, Dahabreh IJ, et al. Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials. Int J Epidemiol 2016;45:dyw118 10.1093/ije/dyw118 [27375287]
[63] Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:311–21 10.1056/NEJMoa1312889 [24450890]
[64] Honig LS, Vellas B, Woodward M, et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. N Engl J Med 2018;378:321–30 10.1056/NEJMoa1705971 [29365294]
[65] Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011;306:2704–14 10.1001/jama.2011.1880 [22203539]
[66] Federico Cappuzzo, Tudor Ciuleanu, Lilia Stelmakh, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study ;
[67] McShane LM, Rothmann MD, Fleming TR. Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seek. Clin Trials 2023:17407745231169692 10.1177/17407745231169692 [37095696]
[68] Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med 2018;378:2288–301 10.1056/NEJMoa1716948 [29863955]
[69] Gregorc V, Novello S, Lazzari C, et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. The Lancet Oncology 2014;15:713–21 10.1016/S1470-2045(14)70162-7
[70] Crippa A, Laere B de, Discacciati A, et al. The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer. Trials 2020;21:579 10.1186/s13063-020-04515-8 [32586393]
[71] Janiaud P, Serghiou S, Ioannidis JPA. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treat Rev 2019;73:20–30 10.1016/j.ctrv.2018.12.003 [30572165]
[72] Garralda E, Dienstmann R, Piris-Giménez A, et al. New clinical trial designs in the era of precision medicine. Mol Oncol 2019;13:549–57 10.1002/1878-0261.12465 [30698321]
[73] Tajik P, Zwinderman AH, Mol BW, et al. Trial Designs for Personalizing Cancer Care: A Systematic Review and Classification. Clin Cancer Res 2013;19:4578–88 10.1158/1078-0432.CCR-12-3722 [23788580]
[74] Mandrekar SJ, Sargent DJ. Design of clinical trials for biomarker research in oncology. Clin Investig (Lond) 2011;1:1629–36 10.4155/CLI.11.152 [22389760]
[75] Zhou T, Ji Y. RoBoT: a robust Bayesian hypothesis testing method for basket trials. Biostatistics 2021;22:897–912 10.1093/biostatistics/kxaa005 [32061093]
[76] Le Tourneau C, Delord J-P, Gonçalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. The Lancet Oncology 2015;16:1324–34 10.1016/S1470-2045(15)00188-6 [26342236]
[77] Roustit M, Demarcq O, Laporte S, et al. Platform trials. Therapie 2023;78:29–38 10.1016/j.therap.2022.12.003 [36529559]
[78] Barker A, Sigman C, Kelloff G, et al. I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy. Clin Pharmacol Ther 2009;86:97–100 10.1038/clpt.2009.68
[79] Zhao A, Larbi M, Miller K, et al. A scoping review of interactive and personalized web-based clinical tools to support treatment decision making in breast cancer. Breast 2022;61:43–57 10.1016/j.breast.2021.12.003 [34896693]
[80] Adsul P, Wray R, Spradling K, et al. Systematic Review of Decision Aids for Newly Diagnosed Patients with Prostate Cancer Making Treatment Decisions. J Urol 2015;194:1247–52 10.1016/j.juro.2015.05.093 [26055824]
[81] Yu L, Li P, Yang S, et al. Web-based decision aids to support breast cancer screening decisions: systematic review and meta-analysis. J Comp Eff Res 2020;9:985–1002 10.2217/cer-2020-0052 [33025800]
[82] Shojaie D, Hoffman AS, Amaku R, et al. Decision Making When Cancer Becomes Chronic: Needs Assessment for a Web-Based Medullary Thyroid Carcinoma Patient Decision Aid. JMIR Form Res 2021;5:e27484 10.2196/27484 [34269691]
[83] Yung A, Kay J, Beale P, et al. Computer-Based Decision Tools for Shared Therapeutic Decision-making in Oncology: Systematic Review. JMIR Cancer 2021;7:e31616 10.2196/31616 [34544680]
[84] Austin CA, Mohottige D, Sudore RL, et al. Tools to Promote Shared Decision Making in Serious Illness: A Systematic Review. JAMA Intern Med 2015;175:1213–21 10.1001/jamainternmed.2015.1679 [25985438]
[85] Blette BS, Granholm A, Li F, et al. Causal Bayesian machine learning to assess treatment effect heterogeneity by dexamethasone dose for patients with COVID-19 and severe hypoxemia. Sci Rep 2023;13:6570 10.1038/s41598-023-33425-3 [37085591]
[86] Zhao Y, Slate EH, Xu C, et al. Empirical comparisons of heterogeneity magnitudes of the risk difference, relative risk, and odds ratio. Syst Rev 2022;11:26 10.1186/s13643-022-01895-7 [35151340]
[87] Steyerberg EW. Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating, 2nd edn. Cham: Springer International Publishing; Imprint: Springer 2019 ISBN:9783030164010;
[88] Riley RD, van der Windt D, Croft P, et al., eds. Prognosis research in healthcare: Concepts, methods, and impact. Oxford, United Kingdom: Oxford University Press 2019.
[89] Alba AC, Agoritsas T, Walsh M, et al. Discrimination and Calibration of Clinical Prediction Models: Users' Guides to the Medical Literature. JAMA 2017;318:1377–84 10.1001/jama.2017.12126 [29049590]
[90] Pencina MJ, D'Agostino RB. Evaluating Discrimination of Risk Prediction Models: The C Statistic. JAMA 2015;314:1063–64 10.1001/jama.2015.11082 [26348755]
[91] van Calster B, McLernon DJ, van Smeden M, et al. Calibration: the Achilles heel of predictive analytics. BMC Med 2019;17:230 10.1186/s12916-019-1466-7 [31842878]
[92] Wolff RF, Moons KGM, Riley RD, et al. PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies. Ann. Intern. Med. 2019;170:51–58 10.7326/m18-1376 [30596875]
[93] Tie J, Cohen JD, Lahouel K, et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N Engl J Med 2022;386:2261–72 10.1056/nejmoa2200075 [35657320]
[94] Sparano JA, Gray RJ, Della Makower F, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2018;379:111–21 10.1056/NEJMoa1804710 [29860917]
[95] Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 2016;375:717–29 10.1056/NEJMoa1602253 [27557300]
[96] Kent DM, Rothwell PM, Ioannidis JPA, et al. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials 2010;11:85 10.1186/1745-6215-11-85 [20704705]
[97] Kent DM, Steyerberg E, van Klaveren D. Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects. BMJ 2018;363:k4245 10.1136/bmj.k4245 [30530757]
[98] Hoogland J, IntHout J, Belias M, et al. A tutorial on individualized treatment effect prediction from randomized trials with a binary endpoint. Stat Med 2021;40:5961–81 10.1002/sim.9154 [34402094]
[99] Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA 2007;298:1209–12 10.1001/jama.298.10.1209 [17848656]
[100] Kent DM, Paulus JK, van Klaveren D, et al. The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement. Ann. Intern. Med. 2020;172:35–45 10.7326/M18-3667 [31711134]
[101] Lipkovich I, Svensson D, Ratitch B, et al. Overview of modern approaches for identifying and evaluating heterogeneous treatment effects from clinical data. Clin Trials 2023:17407745231174544 10.1177/17407745231174544 [37203150]
[102] Kent DM, van Klaveren D, Paulus JK, et al. The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration. Ann. Intern. Med. 2020;172:W1-W25 10.7326/M18-3668 [31711094]
[103] Lipkovich I, Dmitrienko A, B R. Tutorial in biostatistics: data-driven subgroup identification and analysis in clinical trials. Stat Med 2017;36:136–96 10.1002/sim.7064 [27488683]
[104] Lipkovich I, Dmitrienko A, Denne J, et al. Subgroup identification based on differential effect search--a recursive partitioning method for establishing response to treatment in patient subpopulations. Stat Med 2011;30:2601–21 10.1002/sim.4289 [21786278]
[105] Dmitrienko A, Millen B, Lipkovich I. Multiplicity considerations in subgroup analysis. Stat Med 2017;36:4446–54 10.1002/sim.7416 [28762525]
[106] Lipkovich I, Dmitrienko A, Muysers C, et al. Multiplicity issues in exploratory subgroup analysis. J Biopharm Stat 2018;28:63–81 10.1080/10543406.2017.1397009 [29173045]
[107] Rekkas A, Paulus JK, Raman G, et al. Predictive approaches to heterogeneous treatment effects: a scoping review. BMC Med Res Methodol 2020;20:264 10.1186/s12874-020-01145-1 [33096986]
[108] Rekkas A, Paulus JK, Raman G, et al. Predictive approaches to heterogeneous treatment effects: a scoping review. BMC Med Res Methodol 2020;20:264 10.1186/s12874-020-01145-1 [33096986]
[109] Nguyen T-L, Collins GS, Landais P, et al. Counterfactual clinical prediction models could help to infer individualized treatment effects in randomized controlled trials-An illustration with the International Stroke Trial. Journal of Clinical Epidemiology 2020;125:47–56 10.1016/j.jclinepi.2020.05.022 [32464321]
[110] Goligher EC, Lawler PR, Jensen TP, et al. Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19. JAMA 2023 10.1001/jama.2023.3651
[111] Fröhlich H, Balling R, Beerenwinkel N, et al. From hype to reality: data science enabling personalized medicine. BMC Med 2018;16:150 10.1186/s12916-018-1122-7 [30145981]
[112] Eckardt J-N, Rollig C, Kramer M, et al. Prediction of Complete Remission and Survival in Acute Myeloid Leukemia Using Supervised Machine Learning. Blood 2021;138:108 10.1182/blood-2021-149582
[113] Zawadzki P, Woźna A, Sztromwasser P, et al. 1134P Personalized medicine in advanced breast cancer: AI-driven genomic test for CDK4/6 treatment response prediction. Annals of Oncology 2021;32:S925 10.1016/j.annonc.2021.08.776
[114] Sechidis K, Papangelou K, Metcalfe PD, et al. Distinguishing prognostic and predictive biomarkers: an information theoretic approach. Bioinformatics 2018;34:3365–76 10.1093/bioinformatics/bty357 [29726967]
[115] Kesari G (2021). Meet Your Digital Twin: The Coming Revolution In Drug Development. Forbes, 29 September 2021. Available at: https://www.forbes.com/sites/ganeskesari/2021/09/29/meet-your-digital-twin-the-coming-revolution-in-drug-development/?sh=98cc45c745fb Accessed March 20, 2023.
[116] Björnsson B, Borrebaeck C, Elander N, et al. Digital twins to personalize medicine. Genome Med 2020;12:1–4 10.1186/s13073-019-0701-3
[117] Al-Tashi Q, Saad MB, Muneer A, et al. Machine Learning Models for the Identification of Prognostic and Predictive Cancer Biomarkers: A Systematic Review. Int J Mol Sci 2023;24 10.3390/ijms24097781 [37175487]
[118] Trebeschi S, Drago SG, Birkbak NJ, et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Annals of Oncology 2019;30:998–1004 10.1093/annonc/mdz108 [30895304]
[119] Finlayson SG, Beam AL, van Smeden M. Machine Learning and Statistics in Clinical Research Articles-Moving Past the False Dichotomy. JAMA Pediatr 2023 10.1001/jamapediatrics.2023.0034 [36939696]
[120] Hakeem H, Feng W, Chen Z, et al. Development and Validation of a Deep Learning Model for Predicting Treatment Response in Patients With Newly Diagnosed Epilepsy. JAMA Neurol 2022;79:986–96 10.1001/jamaneurol.2022.2514 [36036923]
[121] Falet J-PR, Durso-Finley J, Nichyporuk B, et al. Estimating individual treatment effect on disability progression in multiple sclerosis using deep learning. Nat Commun 2022;13:5645 10.1038/s41467-022-33269-x [36163349]
[122] Temple R. Enrichment of clinical study populations. Clin Pharmacol Ther 2010;88:774–78 10.1038/clpt.2010.233 [20944560]
[123] Bovis F, Carmisciano L, Signori A, et al. Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data. BMC Med 2019;17:113 10.1186/s12916-019-1345-2 [31208412]
[124] Mu W, Jiang L, Zhang J, et al. Non-invasive decision support for NSCLC treatment using PET/CT radiomics. Nat Commun 2020;11:5228 10.1038/s41467-020-19116-x [33067442]
[125] Oikonomou EK, Spatz ES, Suchard MA, et al. Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials. Lancet Digit Health 2022;4:e796-e805 10.1016/S2589-7500(22)00170-4 [36307193]
[126] van Calster B, Steyerberg EW, Wynants L, et al. There is no such thing as a validated prediction model. BMC Med 2023;21:70 10.1186/s12916-023-02779-w [36829188]
[127] Dhiman P, Ma J, Andaur Navarro CL, et al. Risk of bias of prognostic models developed using machine learning: a systematic review in oncology. Diagn Progn Res 2022;6:13 10.1186/s41512-022-00126-w [35794668]
[128] Dhiman P, Ma J, Navarro CA, et al. Reporting of prognostic clinical prediction models based on machine learning methods in oncology needs to be improved. Journal of Clinical Epidemiology 2021;138:60–72 10.1016/j.jclinepi.2021.06.024 [34214626]
[129] Efthimiou O, Hoogland J, Debray TPA, et al. Measuring the performance of prediction models to personalize treatment choice. Stat Med 2023;42:1188–206 10.1002/sim.9665 [36700492]
[130] Wynants L, van Calster B, Collins GS, et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ 2020;369:m1328 10.1136/bmj.m1328 [32265220]
[131] van Klaveren D, Balan TA, Steyerberg EW, et al. Models with interactions overestimated heterogeneity of treatment effects and were prone to treatment mistargeting. Journal of Clinical Epidemiology 2019;114:72–83 10.1016/j.jclinepi.2019.05.029 [31195109]
[132] Olsen MK, Stechuchak KM, Oddone EZ, et al. Which patients benefit most from completing health risk assessments: comparing methods to identify heterogeneity of treatment effects. Health Serv Outcomes Res Method 2021;21:527–46 10.1007/s10742-021-00243-x
[133] Segal JB, Varadhan R, Groenwold RH, et al. Assessing Heterogeneity of Treatment Effect in Real-World Data. Ann. Intern. Med. 2023 10.7326/M22-1510 [36940440]
[134] Claassens DMF, Vos GJA, Bergmeijer TO, et al. A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. N Engl J Med 2019;381:1621–31 10.1056/NEJMoa1907096 [31479209]
[135] Pereira NL, Farkouh ME, So D, et al. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA 2020;324:761–71 10.1001/jama.2020.12443 [32840598]
[136] Collet J-P, Cuisset T, Rangé G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100–09 10.1056/NEJMoa1209979 [23121439]
[137] Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013;369:2283–93 10.1056/NEJMoa1310669 [24251361]
[138] Verhoef TI, Ragia G, Boer A de, et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med 2013;369:2304–12 10.1056/NEJMoa1311388 [24251360]
[139] Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013;369:2294–303 10.1056/NEJMoa1311386 [24251363]
[140] Swen JJ, van der Wouden CH, Manson LE, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. The Lancet 2023;401:347–56 10.1016/S0140-6736(22)01841-4 [36739136]
